Seonix Bio Launches SightScore, the First Clinical Polygenic Risk Score Test for Glaucoma in the US

Seonix Bio announced the US launch of SightScore, which the company descibes as the first commercially available clinical polygenic risk score testing service for primary open-angle glaucoma. Already available in Australia and New Zealand, SightScore utilizes a simple saliva test to identify individuals at high genetic risk for glaucoma, enabling earlier diagnosis, intervention, and more personalized treatment.

SightScore analyzes millions of genetic variants in a patient’s genome to generate a personalized polygenic risk score. The test estimates an individual's genetic risk of developing glaucoma or, for those already diagnosed, assesses the likelihood of disease progression. By providing clinicians with a precise genetic risk assessment, SightScore said it allows for better patient prioritization and management.

“SightScore is a game changer in the way we will assess and manage patients at risk for glaucoma. It is an invaluable tool for identifying individuals who may not show obvious signs of the disease yet and are at higher genetic risk,” Inder Paul Singh, MD, president of The Eye Centers of Racine & Kenosha, in Kenosha, Wisconsin, said in a company news release. “By incorporating SightScore into our practice, we can more effectively prioritize patients for early screening, personalize their care, and ensure we’re detecting glaucoma in its earliest, most treatable stages.”

"In the past, clinical genetic risk assessment for glaucoma has targeted a single gene or tens of genetic variants. As the first truly polygenic clinical genetic risk score for glaucoma on the market, using 7 million genetic variants, SightScore represents a major step forward in how we diagnose and manage this disease," said Nick Haan, CEO of Seonix Bio. "By identifying individuals at high genetic risk through a simple saliva test, we empower clinicians to intervene earlier and ultimately preserve vision.”

SightScore can be referred online by an appropriate health professional and involves a saliva collection process, followed by genetic analysis and the delivery of a clinical report. For more information about SightScore, visit seonixbio.com.